Aurobindo Pharma Limited - Company Snapshot & SWOT Analysis
The key business segments of Aurobindo Pharma are APIs, Formulations, and Packaging, and the company sells over 300 products in over 125 countries. About 35% sales are generated through APIs, and About 65% of the company’s revenue is generated from formulations business, of which 63% of formulation sales comes from United States.
During the period of 2013, the company increased its revenue from INR 58.55 bn to INR 164.99 bn. During the same period 2013-2018, the company registered growth rate of 23.02%.
In the FY 2018, 55% of the revenue came from rest of world (RoW), which is expected to grow at a CAGR of 19.5%, while 45% came from US, which is expected to grow at a CAGR of 10.25%.
Scope of the Aurobindo Pharma Limited - Company Snapshot & SWOT Analysis Report
During the period of 2013, the company increased its revenue from INR 58.55 bn to INR 164.99 bn. During the same period 2013-2018, the company registered growth rate of 23.02%.
In the FY 2018, 55% of the revenue came from rest of world (RoW), which is expected to grow at a CAGR of 19.5%, while 45% came from US, which is expected to grow at a CAGR of 10.25%.
Scope of the Aurobindo Pharma Limited - Company Snapshot & SWOT Analysis Report
- This report provides detailed information about Aurobindo Pharma Limited including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for the global pharmaceutical market.
- This report provides information about current and future trends for the global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Aurobindo Pharma Limited - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Aurobindo Pharma Limited
3.1.1 Company Profile
3.1.2 Aurobindo Pharmaceuticals in Pharma Manufacturing Value Chain
3.1.3 Aurobindo Pharmaceuticals: Financial Performance
3.1.4 Aurobindo Pharmaceuticals: Business Strategy
3.1.5 SWOT Analysis of Aurobindo Pharmaceuticals
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilars
Current Trends
1. INCREASING SEVERITY OF DRUG PRICE CONTROLS
2. GREATER FOCUS ON RARE DISEASES / ORPHAN DRUGS
3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS
4. INCREASING FOCUS ON CELL THERAPY
5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM
6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS
7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
Notes
Company Information
Scope of the Aurobindo Pharma Limited - Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Aurobindo Pharma Limited
3.1.1 Company Profile
3.1.2 Aurobindo Pharmaceuticals in Pharma Manufacturing Value Chain
3.1.3 Aurobindo Pharmaceuticals: Financial Performance
3.1.4 Aurobindo Pharmaceuticals: Business Strategy
3.1.5 SWOT Analysis of Aurobindo Pharmaceuticals
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilars
Current Trends
1. INCREASING SEVERITY OF DRUG PRICE CONTROLS
2. GREATER FOCUS ON RARE DISEASES / ORPHAN DRUGS
3. INCREASING DEVELOPMENT OF NUCLEIC ACIDS AS THERAPEUTICS
4. INCREASING FOCUS ON CELL THERAPY
5. IMPLANTABLES (BIOELECTRONICS) AND ELECTROCEUTICALS ARE EXPECTED TO BECOME MAINSTREAM
6. USE OF 3D PRINTING TO REDUCE COST AND IMPROVE PRODUCTION EFFICIENCY OF BIOLOGICS
7. INCREASING USE OF BIG DATA AND ARTIFICIAL INTELLIGENCE (AI) IN DRUG DISCOVERY
Notes
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Aurobindo Pharma Limited
Exhibit 3.2 Contact Information of Aurobindo Pharma Limited
Exhibit 3.3 Aurobindo Pharma Limited in Pharma Manufacturing Value Chain
Exhibit 3.4 Aurobindo Pharma Limited Revenue 2010-2014 (in INR billion)
Exhibit 3.5 Year-wise Aurobindo Pharma Limited Revenue Growth 2010-14 (in %)
Exhibit 3.6 Source wise revenue share of Aurobindo Pharma Ltd. (in %)
Exhibit 3.7 Source wise Revenue CAGR growth forecast for Aurobindo Pharma Ltd. 2018-23 (in %)
Exhibit 3.8 Forecast of Aurobindo Pharma Ltd. 2018-23 (in INR billions)
Exhibit 3.9 Growth Forecast of US Market for Aurobindo Pharma Ltd. 2018-23 (in INR bn)
Exhibit 3.10 Growth forecast of Rest of World for Aurobindo Pharma Ltd. 2018-23 (in INR bn)
Exhibit 3.11 SWOT Analysis of Aurobindo Pharmaceuticals
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Aurobindo Pharma Limited
Exhibit 3.2 Contact Information of Aurobindo Pharma Limited
Exhibit 3.3 Aurobindo Pharma Limited in Pharma Manufacturing Value Chain
Exhibit 3.4 Aurobindo Pharma Limited Revenue 2010-2014 (in INR billion)
Exhibit 3.5 Year-wise Aurobindo Pharma Limited Revenue Growth 2010-14 (in %)
Exhibit 3.6 Source wise revenue share of Aurobindo Pharma Ltd. (in %)
Exhibit 3.7 Source wise Revenue CAGR growth forecast for Aurobindo Pharma Ltd. 2018-23 (in %)
Exhibit 3.8 Forecast of Aurobindo Pharma Ltd. 2018-23 (in INR billions)
Exhibit 3.9 Growth Forecast of US Market for Aurobindo Pharma Ltd. 2018-23 (in INR bn)
Exhibit 3.10 Growth forecast of Rest of World for Aurobindo Pharma Ltd. 2018-23 (in INR bn)
Exhibit 3.11 SWOT Analysis of Aurobindo Pharmaceuticals
